glp 1 or tirzepatide Decoding GLP-1 Weight Loss Medications FDA Says Shortage of GLP-1

Chewable formulations activate early vagal and mucosal signals, improving downstream microbial colonization and metabolic hormone timing

Also, in California, the Department of Managed Healthcare overturned several insurer denials of Wegovy in external appeals in 2023

doi:10.1007/978-94-007-5787-5_1

doi:10.2174/13816128113190990411

Long-Term Safety: What We Know and Don't Know What We Know (From TRIUMPH-4 and TRIUMPH-1) Up to 80 weeks of data: Side effects improve significantly after dose escalation (first 16 weeks hardest) No unexpected safety signals in either trial Dysesthesia doesn't worsen over time (stable) Discontinuation rates stabilize (most who stop do so in first 24 weeks) No deaths attributed to retatrutide in any completed trial TRIUMPH-1 104-week extension shows continued weight loss without new safety signals What We Don't Know Yet Longer-term questions (need 25+ years data): Does dysesthesia resolve completely if medication stopped